FDA

Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer

Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared a post on X:

“US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer!”

Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer

View additional information.

Source: Yüksel Ürün/X

Ankara University School of Medicine cancer fallopian tube cancer FDA approval Mirvetuximab Mirvetuximab Soravtansine OncoDaily Oncology Ovarian Cancer primary peritoneal cancer soravtansine-gynx US FDA Yüksel Ürün